Condition category
Circulatory System
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Animal and human studies suggest that mild hypothermia (low body temperature) has a beneficial effect for stroke and heart attack patients. The aim of this study is to investigate the feasibility and safety of using surface cooling to induce mild hypothermia (32-34°C) in healthy, conscious volunteers.

Who can participate?
Healthy volunteers aged 18 to 70

What does the study involve?
Surface cooling involves using a cooling pad to achieve a target temperature of 32-34°C for six hours. Shivering is prevented with drugs such as meperidine and buspirone and additional magnesium in eight of the participants. Core temperature is measured continuously with a temperature probe inserted through the nose into the esophagus (gullet). To avoid discomfort and vomiting a local anesthestic is applied. Comfort is assessed every 10 minutes during initial cooling, and every 30 minutes during maintenance cooling. Participants are monitored for shivering. In case of shivering or a low comfort score, more meperidine and meperidine are given to the participant. At the end of the observational period, the participants’ skin is examined by a dermatologist.

What are the possible benefits and risks of participating?
There are no immediate benefits for the participants. When hypothermic treatment begins and the body temperature begins to drop, there will be mild increase in heart rate followed by a decrease in the heart rate as the temperature drops below 35.5°C, with a decrease in heart rate as temperature decreases further. Hypothermia weakens the immune functions and interferes with various inflammatory responses. Most studies using hypothermia for 24 hours or less have reported no or only small increases in infection rates. In initial studies with the device only minimal skin redness was observed, which resolved within minutes after removal of the blankets. No skin lesions were observed during the observation period. Platelet count and function and the body’s mechanism to stop bleeding (coagulation) are impaired during hypothermia but bleeding problems are rare. No hypothermia study has reported significant problems with bleeding. The effect of meperidine on breathing and blood circulation is not clinically significant in healthy volunteers. No relevant effects of buspirone on breathing and blood circulation have been observed.

Where is the study run from?
Medical University of Vienna (Austria)

When is the study starting and how long is it expected to run for?
March to April 2011

Who is funding the study?
Emergency Medical Cooling Systems AG (Austria)

Who is the main contact?
Prof. Bernd Jilma

Trial website

Contact information



Primary contact

Prof Bernd Jilma


Contact details

Department of Clinical Pharmacology
Medical University of Vienna
Vienna General Hospital
Währinger Gürtel 18-20

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Surface cooling for induction of mild Hypothermia In Conscious Healthy Volunteers: a feasibility trial



Study hypothesis

To investigate the feasibility and safety of non-invasive surface cooling for induction and maintenance of mild hypothermia (32-34°C) in healthy, conscious volunteers.

Ethics approval

Ethics Committee of the Medical University of Vienna, 16/06/2009, Nr: 470/2009

Study design

Prospective interventional cohort study

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Stroke, acute myocardial infarction, cardiogenic shock


Volunteers with an age of 18 to 70 years are included. After baseline measurements, meperidine (Alodan®, Gerot, Vienna, Austria) 1 mg/kg bolus, followed by 30 mg/h intravenously, and buspirone (Buspar®, Bristol-Myers Squibb, Meymac, France) 30 mg orally once will be given to prevent shivering. A single bolus of granisetron hydrochloride(Kytril®, Roche Austria, Vienna, Austria) 3 mg will be administered intravenously to prevent nausea. A continuous fluid drip with an isotonic electrolyte solution (Elomel iso®, Fresenius Kabi Austria, Graz, Austria) with an infusion rate of 100 ml/h will be administered throughout the cooling period. After eight subjects additionally a bolus of 4 g magnesium sulfate (MgSO4) over 30 minutes followed by a continuous intravenous drip of 2 g/h for 150 minutes will be given.

The cooling pads (EMCOOLSpad®, Emcools AG, Pfaffstaetten, Austria), each 20 x 30 cm, consists of multiple cooling cells filled with a patented cooling gel. The inner layer is a biocompatible film, that adheres to the patient’s skin on application and provides intimate pad to skin contact for efficient heat transfer. The cooling units are stored in a cooling box at -2°C before use. Six cooling units will be applied on back, thorax, abdomen, and thighs of the volunteers. The cooling units will be removed when a core temperature of 35°C is reached. Target core temperature will be 32-34°C and maintained for six hours.

Intervention type



Not Applicable

Drug names

Primary outcome measure

Core temperature measured continuously with a temperature probe (Mon-a-therm® 9Fr/Ch; Tyco Healthcare, Mansfield, USA) advanced into the esophagus

Secondary outcome measures

1. Comfort score recorded every 10 minutes during initial cooling, and every 30 minutes during maintenance cooling
2. Shivering using a 4-point scale: 0 = no shivering evident; 1 = isolated facial or masticatory fasciculation; 2 = peripheral shivering; 3 = uncontrolled rigor
3. Skin examination using a 5-points scale (severe - frost bites; moderate - skin trauma; medium - red skin; mild - pink skin; no visible skin irritation)

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Volunteers aged 18 to 70 years

Participant type

Healthy volunteer

Age group




Target number of participants


Total final enrolment


Participant exclusion criteria

1. Pregnant women
2. Subjects with a known pre-existing cardiopulmonary disease or pre-existing malignancy
3. A pre-existing coagulopathy
4. An active dermatologic condition
5. Current treatment with monamineoxidase inhibitors
6. Previous or current drug abuse
7. Known allergy to the study medication

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Medical University of Vienna

Sponsor information


Emergency Medical Cooling Systems (EMCOOL) AG (Austria)

Sponsor details

Brucknerstrasse 6/7a

Sponsor type




Funder type


Funder name

EMCOOLS AG (Austria)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2011 results in (added 23/10/2020)

Publication citations

Additional files

Editorial Notes

23/10/2020: The following changes were made to the trial record: 1. Publication reference added. 2. The total final enrolment was added. 05/10/2016: Plain English summary added.